ESTIMATIONNCT07789574
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Enrollment reopened Show 4 more changesShow less
- Lead sponsor: Thomas Ernst, PD Dr. med. to Thomas Ernst, Prof. Dr. med.
- Start date: Jun 22, 2026 to Nov 2026
- Eligibility criteria expanded, about 30 words
- Trial sites expanded: 1 → 10 locations
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Rate of MR2 at 12 months
Timeframe: 12 months after start of therapy
Arms and interventions
asciminib 200 mg BIDExperimental
All patients will be treated with asciminib 200 mg BID
Drugs: asciminib 200 mg BID
Sites
10 sites in 1 country